Index Entries

Evgeny N. Mikhaylov, Tamara A. Lyubimtseva, Aleksandr D. Vakhrushev, Dmitry Stepanov, Dmitry S. Lebedev, Elena Yu. Vasilieva, Alexandra O. Konradi, and Evgeny V. Shlyakhto
January 29, 2022
Interdisciplinary Perspectives on Infectious Diseases
Almazov National Medical Research Centre (Russia)

Introduction: … We aimed to assess the preventive potential of regular bromhexine hydrochloride intake for reduction of the risk of COVID-19 in medical staff actively involved in the evaluation and treatment of patients with confirmed or suspected SARS-CoV-2 infection. The study was conducted in the period before any vaccine against COVID-19 became available…

Discussion: Although generally underpowered, the present study has several important findings. The primary combined endpoint, the rate of positive nasopharyngeal swab PCR tests for SARS-CoV-2 or symptomatic COVID-19, was similar in both groups. However, there was a trend towards a lower rate of the positive swab PCR test in the bromhexine hydrochloride treatment group. Importantly, the rate of clinically significant SARS-CoV-2 infection was statistically lower in the treatment group (0/25 participants) compared with the control group (5/25 participants).”

document
bromhexine,COVID-19,medical treatments,pharmaceuticals